Dirk Brehmer

Johnson & Johnson (United States) — United States

Medicine · Health Sciences

21h-index3.2kcitations63works0.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(16), Cancer-related gene regulation(12), FOXO transcription factor regulation(8), Heat shock proteins research(7), Chronic Myeloid Leukemia Treatments(7)

Publications63 total

JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G
iScience·2025· 4 citedOpen Access
Supplementary Methods from Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
2024Open Access
Data from Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
2024Open Access
Supplementary Tables from Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
2024Open Access
Supplementary Figures from Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
2024Open Access
Supplementary Tables from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
2023Open Access
Supplementary Tables from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
2023Open Access
Data from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
2023Open Access
Supplementary Figures from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
2023Open Access
Data from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
2023Open Access
Supplementary Figures from <i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
2023Open Access
Data from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
2023Open Access
Supplementary Table 1 from Cellular Targets of Gefitinib
2023Open Access
Supplementary Methods from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
2023Open Access
Supplementary Figure 1 from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
2023Open Access
Supplementary Table 1 from Cellular Targets of Gefitinib
2023Open Access
Supplementary Methods and Figure from Cellular Targets of Gefitinib
2023Open Access
Data from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
2023Open Access
Supplementary Table 2 from Cellular Targets of Gefitinib
2023Open Access
Data from Cellular Targets of Gefitinib
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Henrik Daub(14), Klaus Godl(13), Lijs Beke(13), Erika van Heerde(13), Josef Wissing(12), Marc Paradé(11), Stephanie Blencke(11), Matthew Cotten(11), Joannes T. M. Linders(11), Gÿorgý Kéri(10), Lieven Meerpoel(10), Stefan C. Müller(9), An Boeckx(9), Matthew V. Lorenzi(8), Tongfei Wu(8), Sylvie Laquerre(8), Michael Weber(8), Souichi Ogata(7), Hillary J. Millar(7), Idoya Lahortiga(6)